Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Covid-19: Australian Competition Body Confirms Industry Collaboration Conditions

Executive Summary

A collaboration between the Australian Generic and Biosimilar Medicines Association and brand industry body Medicines Australia against the backdrop of COVID-19 has been endorsed through a final determination from the country’s competition body that clarifies the conditions of the ongoing arrangement.

You may also be interested in...



Australian Body Welcomes Passage Of Shortages Law

Legislation setting out measures to mitigate shortages in Australia has been passed by the country’s senate, incorporating into law key provisions of new five-year pact between the off-patent industry and the government.

Australia's Competition Regulator Authorizes Another Year Of Close Collaboration

Australian off-patent industry association GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the Australian Competition and Consumer Commission has decided, extending an existing authorization by a further year.

Another Year Of Close Collaboration Authorized In Australia

Australian off-patent industry association the GBMA and brand body Medicines Australia can continue to collaborate closely as part of work to mitigate shortages in the context of the COVID-19 pandemic, the ACCC has decided, extending an existing authorization by a further year.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS145399

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel